-
1.发明授权
公开(公告)号：US6004972A
公开(公告)日：1999-12-21
申请号：US103105
申请日：1998-06-23
IPC分类号： A61K31/00 , A61K31/13 , A61K31/15 , A61K31/166 , A61K31/195 , A61K31/221 , A61K31/35 , A61K31/352 , A61K31/40 , A61K31/405 , A61K31/435 , A61K31/439 , A61K31/445 , A61K31/4515 , A61K31/454 , A61K31/46 , A61K31/475 , A61K31/48 , A61K31/54 , A61K31/5415 , A61K31/55 , A61K31/551 , A61K31/5513 , A61K31/695 , A61K38/22 , A61K45/06 , G01N33/74 , A61K31/44
CPC分类号： G01N33/74 , A61K31/00 , A61K31/13 , A61K31/15 , A61K31/166 , A61K31/195 , A61K31/221 , A61K31/35 , A61K31/352 , A61K31/40 , A61K31/405 , A61K31/435 , A61K31/439 , A61K31/445 , A61K31/4515 , A61K31/454 , A61K31/46 , A61K31/475 , A61K31/48 , A61K31/4985 , A61K31/54 , A61K31/5415 , A61K31/55 , A61K31/551 , A61K31/5513 , A61K31/695 , A61K38/2257 , A61K45/06 , Y10S514/866
摘要： A process for the long term modification and regulation of lipid and carbohydrate metabolism--generally to reduce obesity, insulin resistance, and hyperinsulinemia or hyperglycemia, or both (these are the hallmarks of noninsulin dependent, or Type II diabetes)--by administration (i.e., by oral, sublingual or parenternal administration) to a vertebrate, animal or human, of a dopamine agonist, e.g., bromocriptine. Administration of the bromocriptine is made over a limited period at a time of day dependent on the normal circadian rhythm of insulin resistant and insulin sensitive members of a similar species. Insulin resistance, and hyperinsulinemia and hyperglycemia, or both, can be controlled in humans on a long term basis by such treatment inasmuch as the short term daily administration resets hormonal timing in the neural centers of the brain to produce long term effects.
摘要翻译： 长期改变和调节脂质和碳水化合物代谢的过程 - 通常通过给药（即，通过给药（例如，通过给药）而减少肥胖，胰岛素抵抗和高胰岛素血症或高血糖或两者（这些是非胰岛素依赖型或II型糖尿病的特征） 通过口服，舌下或本体给药）到脊髓动物或动物或人类的多巴胺激动剂，例如溴隐亭。 溴隐亭的施用在一天的有限时间内取决于相似物种的胰岛素抵抗和胰岛素敏感成员的正常昼夜节律。 胰岛素抵抗和高胰岛素血症和高血糖或两者都可以通过这种治疗长期控制在人类中，因为短期每日给药复位脑神经中枢的激素时间以产生长期效应。
-
2.发明授权
公开(公告)号：US5866584A
公开(公告)日：1999-02-02
申请号：US465818
申请日：1995-06-06
IPC分类号： A61K31/00 , A61K31/13 , A61K31/15 , A61K31/166 , A61K31/195 , A61K31/221 , A61K31/35 , A61K31/352 , A61K31/40 , A61K31/405 , A61K31/435 , A61K31/439 , A61K31/445 , A61K31/4515 , A61K31/454 , A61K31/46 , A61K31/475 , A61K31/48 , A61K31/496 , A61K31/54 , A61K31/5415 , A61K31/55 , A61K31/551 , A61K31/5513 , A61K31/695 , A61K38/22 , A61K45/00 , A61K45/06 , A61P3/08 , A61P3/10 , C07D457/00 , C07D457/04 , G01N33/74 , A61K31/44
CPC分类号： A61K31/496 , A61K31/00 , A61K31/13 , A61K31/15 , A61K31/166 , A61K31/195 , A61K31/221 , A61K31/35 , A61K31/352 , A61K31/40 , A61K31/405 , A61K31/435 , A61K31/439 , A61K31/445 , A61K31/4515 , A61K31/454 , A61K31/46 , A61K31/475 , A61K31/48 , A61K31/4985 , A61K31/54 , A61K31/5415 , A61K31/55 , A61K31/551 , A61K31/5513 , A61K31/695 , A61K38/2257 , A61K45/06 , G01N33/74 , Y10S514/866
摘要： A process for the long term modification and regulation of lipid and carbohydrate metabolism--generally to reduce obesity, insulin resistance, and hyperinsulinemia or hyperglycemia, or both (these are the hallmarks of noninsulin dependent, or Type II diabetes)--by administration (i.e., by oral, sublingual or parenternal administration) to a vertebrate, animal or human, of a dopamine agonist, e.g., bromocriptine. Administration of the bromocriptine is made over a limited period at a time of day dependent on the normal circadian rhythm of insulin resistant and insulin sensitive members of a similar species. Insulin resistance, and hyperinsulinemia and hyperglycemia, or both, can be controlled in humans on a long term basis by such treatment inasmuch as the short term, daily administration resets hormonal timing in the neural centers of the brain to produce long term effects.
摘要翻译： 长期改变和调节脂质和碳水化合物代谢的过程 - 通常通过给药（即，通过给药（例如，通过给药）而减少肥胖，胰岛素抵抗和高胰岛素血症或高血糖或两者（这些是非胰岛素依赖型或II型糖尿病的特征） 通过口服，舌下或本体给药）到脊髓动物或动物或人类的多巴胺激动剂，例如溴隐亭。 溴隐亭的施用在一天的有限时间内取决于相似物种的胰岛素抵抗和胰岛素敏感成员的正常昼夜节律。 胰岛素抵抗和高胰岛素血症和高血糖或两者都可以通过这种治疗长期控制在人类中，因为短期内，每日给药复位脑神经中枢的激素时间以产生长期效果。
-
3.发明授权Therapeutic package for the long term reduction of body fat stores insulin resistance hyperinsulinemia and hyperglycemia in vertebrates 失效长期减少身体脂肪的治疗包装存在胰岛素抵抗高胰岛素血症和脊椎动物高血糖症
公开(公告)号：US5854255A
公开(公告)日：1998-12-29
申请号：US843760
申请日：1997-04-21
IPC分类号： A61K31/00 , A61K31/13 , A61K31/137 , A61K31/15 , A61K31/166 , A61K31/195 , A61K31/221 , A61K31/35 , A61K31/352 , A61K31/40 , A61K31/405 , A61K31/435 , A61K31/439 , A61K31/445 , A61K31/4515 , A61K31/454 , A61K31/46 , A61K31/475 , A61K31/48 , A61K31/496 , A61K31/54 , A61K31/5415 , A61K31/55 , A61K31/551 , A61K31/5513 , A61K31/695 , A61K38/22 , A61K45/00 , A61K45/06 , A61P3/06 , A61P3/08 , A61P3/10 , C07D457/00 , C07D457/04 , G01N33/74 , A61K31/44 , A61K31/495
CPC分类号： G01N33/74 , A61K31/00 , A61K31/13 , A61K31/137 , A61K31/15 , A61K31/166 , A61K31/195 , A61K31/221 , A61K31/35 , A61K31/352 , A61K31/40 , A61K31/405 , A61K31/435 , A61K31/439 , A61K31/445 , A61K31/4515 , A61K31/454 , A61K31/46 , A61K31/475 , A61K31/48 , A61K31/496 , A61K31/4985 , A61K31/54 , A61K31/5415 , A61K31/55 , A61K31/551 , A61K31/5513 , A61K31/695 , A61K38/2257 , A61K45/06 , Y10S514/866 , Y10S514/909
摘要： A therapeutic package for dispensing to, or for use in dispensing to, a vertebrate being treated for a metabolic condition selected from the group consisting of obesity, insulin resistance, hyperinsulinemia, and hyperglycemia comprising one or more unit doses of bromocriptine and labeling directing the use of the package in the treatment of the metabolic condition in a dosage regimen under which the delivery of the bromocriptine is confined to the period during the day near the time of day at which the serum prolactin concentration of a lean, insulin sensitive vertebrate of the same sex is low, and further directing the use of said package in conjunction with the concomitant administration to the vertebrate of one or more unit doses providing a therapeutically effective amount of a prolactin stimulator in a dosage regimen under which the delivery of the prolactin stimulator is confined to the period during the day after the time at which the serum prolactin concentration of a lean, insulin-sensitive vertebrate of the same sex reaches its lowest point and prior to the time of day when the prolactin concentration rises to a peak in lean, insulin-sensitive vertebrates of the same sex.
摘要翻译： 一种用于分配给或用于分配给被选择为选自肥胖症，胰岛素抵抗，高胰岛素血症和高血糖的代谢疾病的脊椎动物的治疗包，其包含一个或多个单位剂量的溴隐亭和指示使用的标记 该药物治疗代谢状况的剂量方案，其中溴隐亭的递送被限制在白天接近白天的贫血，胰岛素敏感性脊椎动物的血清催乳素浓度的同一时间段 性别低，并且进一步将所述包装的使用与所述脊椎动物联合给予脊椎动物一种或多种单位剂量，在剂量方案中提供治疗有效量的催乳素刺激剂，在该方案中，催乳激素刺激剂的输送被限制 到血清催乳素浓度的一段时间之后的一天中， 相同性别的ulin敏感脊椎动物达到其最低点，并且在同一性别的瘦，胰岛素敏感的脊椎动物中的催乳素浓度上升到峰值之前的时间之前。
-
公开(公告)号：US5744477A
公开(公告)日：1998-04-28
申请号：US178569
申请日：1994-01-07
IPC分类号： C07D519/02 , A61K31/00 , A61K31/13 , A61K31/135 , A61K31/137 , A61K31/15 , A61K31/166 , A61K31/195 , A61K31/221 , A61K31/35 , A61K31/352 , A61K31/40 , A61K31/405 , A61K31/435 , A61K31/439 , A61K31/44 , A61K31/445 , A61K31/4515 , A61K31/454 , A61K31/46 , A61K31/475 , A61K31/48 , A61K31/54 , A61K31/5415 , A61K31/55 , A61K31/551 , A61K31/5513 , A61K31/695 , A61K38/22 , A61K45/00 , A61K45/06 , A61P3/04 , A61P3/06 , A61P3/08 , A61P43/00 , G01N33/74
CPC分类号： A61K31/4985 , A61K31/00 , A61K31/13 , A61K31/137 , A61K31/15 , A61K31/166 , A61K31/195 , A61K31/221 , A61K31/35 , A61K31/352 , A61K31/40 , A61K31/405 , A61K31/435 , A61K31/439 , A61K31/445 , A61K31/4515 , A61K31/454 , A61K31/46 , A61K31/475 , A61K31/48 , A61K31/54 , A61K31/5415 , A61K31/55 , A61K31/551 , A61K31/5513 , A61K31/695 , A61K38/2257 , A61K45/06 , G01N33/74 , Y10S514/866 , Y10S514/884 , Y10S514/909
摘要： The present invention is directed to an improvement in a method of weight and/or body-fat reduction comprising a (preferably moderate) reduction in the caloric intake of a subject in need of such treatment in combination with administration to said subject of a prolactin inhibitor. Additionally, the present invention is directed to an improvement in a method for altering and/or resetting prolactin profiles (and thereby controlling one or more metabolic disorders such as obesity, excessive body fat, hyperlipidemia, hyperlipoproteinemia, hyperglycemia, hypercholesterolemia, hyperinsulinemia, insulin resistance, glucose intolerance, and Type II diabetes) comprising administration to a subject in need of such treatment of a prolactin inhibitor at a predetermined time or times during a 24-hour period in combination with a (preferably moderate) reduction of the caloric intake of said subject.
摘要翻译： 本发明涉及一种重量和/或体脂肪减少方法的改进，包括需要这种治疗的受试者的热量摄入减少（优选中等），与给予所述受试者的催乳素抑制剂组合 。 此外，本发明涉及一种用于改变和/或重置催乳素谱（从而控制一种或多种代谢性疾病如肥胖，身体过量脂肪，高脂血症，高脂蛋白血症，高血糖症，高胆固醇血症，高胰岛素血症，胰岛素抵抗）的方法的改进 ，葡萄糖不耐受和II型糖尿病），其包括在24小时内预定时间或时间对需要这种治疗催乳激素抑制剂的受试者施用，与所述的 学科。
-
5.发明授权Process for therapeutically modifying and resetting prolactin rhythm with a dopamine agonist 失效用多巴胺激动剂治疗性修饰和重新配置催乳素节律的方法
公开(公告)号：US5716962A
公开(公告)日：1998-02-10
申请号：US465820
申请日：1995-06-06
IPC分类号： A61K31/00 , A61K31/13 , A61K31/15 , A61K31/166 , A61K31/195 , A61K31/221 , A61K31/35 , A61K31/352 , A61K31/40 , A61K31/405 , A61K31/435 , A61K31/439 , A61K31/445 , A61K31/4515 , A61K31/454 , A61K31/46 , A61K31/475 , A61K31/48 , A61K31/54 , A61K31/5415 , A61K31/55 , A61K31/551 , A61K31/5513 , A61K31/695 , A61K38/22 , A61K45/06 , G01N33/74 , A61K31/44
CPC分类号： G01N33/74 , A61K31/00 , A61K31/13 , A61K31/15 , A61K31/166 , A61K31/195 , A61K31/221 , A61K31/35 , A61K31/352 , A61K31/40 , A61K31/405 , A61K31/435 , A61K31/439 , A61K31/445 , A61K31/4515 , A61K31/454 , A61K31/46 , A61K31/475 , A61K31/48 , A61K31/4985 , A61K31/54 , A61K31/5415 , A61K31/55 , A61K31/551 , A61K31/5513 , A61K31/695 , A61K38/2257 , A61K45/06 , Y10S514/866
摘要： A process for the long term modification and regulation of lipid and carbohydrate metabolism--generally to reduce obesity, insulin resistance, and hyperinsulinemia or hyperglycemia, or both (these are the hallmarks of noninsulin dependent, or Type II diabetes)--by administration (i.e., by oral, sublingual or parenternal administration) to a vertebrate, animal or human, of a dopamine agonist, e.g., bromocriptine. Administration of the bromocriptine is made over a limited period at a time of day dependent on the normal circadian rhythm of insulin resistant and insulin sensitive members of a similar species. Insulin resistance, and hyperinsulinemia and hyperglycemia, or both, can be controlled in humans on a long term basis by such treatment inasmuch as the short term daily administration resets hormonal timing in the neural centers of the brain to produce long term effects.
摘要翻译： 长期改变和调节脂质和碳水化合物代谢的过程 - 通常通过给药（即，通过给药（例如，通过给药）而减少肥胖，胰岛素抵抗和高胰岛素血症或高血糖或两者（这些是非胰岛素依赖型或II型糖尿病的特征） 通过口服，舌下或本体给药）到脊髓动物或动物或人类的多巴胺激动剂，例如溴隐亭。 溴隐亭的施用在一天的有限时间内取决于相似物种的胰岛素抵抗和胰岛素敏感成员的正常昼夜节律。 胰岛素抵抗和高胰岛素血症和高血糖或两者都可以通过这种治疗长期控制在人类中，因为短期每日给药复位脑神经中枢的激素时间以产生长期效应。
-
公开(公告)号：US5716932A
公开(公告)日：1998-02-10
申请号：US450917
申请日：1995-05-26
IPC分类号： A61K31/00 , A61K31/221 , A61K31/352 , A61K31/475 , A61K31/5513 , A61K38/22 , A61K45/06 , G01N33/74 , C07K14/64 , A61K38/00 , C07K9/00
CPC分类号： A61K31/4985 , A61K31/00 , A61K31/221 , A61K31/352 , A61K31/475 , A61K31/5513 , A61K38/2257 , A61K45/06 , G01N33/74
摘要： A process for the long term modification and regulation of lipid metabolism--generally to reduce obesity, insulin resistance, and hyperinsulinemia (the three hallmarks of Type II diabetes)--by injections into the bloodstream of a vertebrate, animal or human, of prolactin, or both prolactin and a glucocorticosteroid. The injections are made over a limited period at a time of day dependent on the normal circadian rhythm of fat and lean members of a similar species. Decreases (or increases) in body fat deposits result by treatment of an obese species (lean species) on a daily timed sequence based on circadian rhythms of the peak prolactin, or peak prolactin and peak glucocorticosteroid, blood level established for lean members (or obese members) of a similar species. Insulin resistance, and hyperinsulinemia can also be controlled in humans on a long term basis by treatment corresponding to that of the treatment for obesity. The short term daily injections reset hormonal timing in the neural centers of the brain to produce long term effects.
-
公开(公告)号：US5696128A
公开(公告)日：1997-12-09
申请号：US271881
申请日：1994-07-07
IPC分类号： A61K45/00 , A61K31/00 , A61K31/135 , A61K31/137 , A61K31/165 , A61K31/166 , A61K31/40 , A61K31/405 , A61K31/415 , A61K31/42 , A61K31/445 , A61K31/4515 , A61K31/454 , A61K31/475 , A61K31/48 , A61K31/54 , A61K31/5415 , A61K31/565 , A61K38/22 , A61K45/06 , A61P29/00 , A61P37/02 , A61P37/04 , A61P37/06 , A01N43/42 , A61K31/44
CPC分类号： A61K38/225 , A61K31/00 , A61K31/137 , A61K31/166 , A61K31/40 , A61K31/405 , A61K31/445 , A61K31/4515 , A61K31/454 , A61K31/475 , A61K31/48 , A61K31/4985 , A61K31/5415 , A61K38/2257 , A61K45/06
摘要： Disclosed are methods for rectifying or ameliorating abnormal responses of mammalian immune systems. Also disclosed are methods for modifying normal responses of the mammalian immune system. Further disclosed are methods for accomplishing the foregoing by administering to a mammal a prolactin reducer and/or enhancer at a pre-determined time or times during a 24-hour period that results in modification of the mammal's abnormal prolactin profile so that it approaches or conforms to the prolactin profile of a young, healthy mammal of the same species (or to a standard profile generated from such individuals). Additionally, methods of upregulating or augmenting an immune response in a mammal are disclosed.
摘要翻译： 公开了用于整流或改善哺乳动物免疫系统的异常反应的方法。 还公开了用于修饰哺乳动物免疫系统的正常反应的方法。 进一步公开的是通过在哺乳动物的异常催乳素特征的修改中在预定时间或24小时期间向哺乳动物施用催乳素还原剂和/或增强剂来实现上述方法，使得其接近或符合 对于同一物种的年轻健康哺乳动物（或由这些个体产生的标准概况）的催乳素特征。 此外，公开了在哺乳动物中上调或增加免疫应答的方法。
-
8.发明授权Method for modifying or resetting the prolactin rhythm of an insulin insensitive or diabetic animal or human 失效改善或重置胰岛素不敏感或糖尿病动物或人类的催乳素节律的方法
公开(公告)号：US5635512A
公开(公告)日：1997-06-03
申请号：US460858
申请日：1995-06-05
IPC分类号： A61K31/00 , A61K31/13 , A61K31/137 , A61K31/15 , A61K31/166 , A61K31/195 , A61K31/221 , A61K31/35 , A61K31/352 , A61K31/40 , A61K31/405 , A61K31/435 , A61K31/439 , A61K31/445 , A61K31/4515 , A61K31/454 , A61K31/46 , A61K31/475 , A61K31/48 , A61K31/496 , A61K31/54 , A61K31/5415 , A61K31/55 , A61K31/551 , A61K31/5513 , A61K31/695 , A61K38/22 , A61K45/00 , A61K45/06 , A61P3/06 , A61P3/08 , A61P3/10 , C07D457/00 , C07D457/04 , G01N33/74 , A61K31/44 , A61K31/50 , A61K31/515
CPC分类号： G01N33/74 , A61K31/00 , A61K31/13 , A61K31/137 , A61K31/15 , A61K31/166 , A61K31/195 , A61K31/221 , A61K31/35 , A61K31/352 , A61K31/40 , A61K31/405 , A61K31/435 , A61K31/439 , A61K31/445 , A61K31/4515 , A61K31/454 , A61K31/46 , A61K31/475 , A61K31/48 , A61K31/496 , A61K31/4985 , A61K31/54 , A61K31/5415 , A61K31/55 , A61K31/551 , A61K31/5513 , A61K31/695 , A61K38/2257 , A61K45/06 , Y10S514/866 , Y10S514/909
摘要： A process for the long term modification and regulation of linid and glucose metabolism--generally to reduce obesity, insulin resistance, and hyperinsulinemia or hyperglycemia, or both (these being the hallmarks of noninsulin dependent, or Type II diabetes)--by administration to a vertebrate, animal or human, of a dopamine agonist and a prolactin stimulator. The dopamine agonist and prolactin stimulator are administered in daily dosages, respectively, at a time of day dependent on the normal circadian rhythm of fat and lean members of a similar species. Decreases in body fat deposits result by treatment of an obese species on a daily timed sequence based on circadian rhythms of the peak prolactin, or peak prolactin and peak glucocorticosteroid, blood level established for lean insulin sensitive members of a similar species. The dopamine agonist is administered at the time of, or just after the time of peak plasma prolactin concentration found in lean animals of the same species and the prolactin stimulator is administered at a time just before the plasma prolactin rhythm reaches its peak in lean animals. Insulin resistance, and hyperinsulinemia or hyperglycemia, or both, can also be controlled in humans on a long term basis by treatment corresponding to that of the treatment for obesity. The short term daily injections reset hormonal timing in the neural centers of the brain to produce long term effects.
摘要翻译： 长期改变和调节线粒体和葡萄糖代谢的过程 - 通常通过给脊椎动物施用来减少肥胖，胰岛素抵抗和高胰岛素血症或高血糖或两者（这些是非胰岛素依赖型或II型糖尿病的特征） 动物或人类的多巴胺激动剂和催乳素刺激剂。 多巴胺激动剂和催乳素刺激剂分别以每天的剂量施用，取决于类似物种的脂肪和瘦成员的正常昼夜节律。 基于妊娠峰值催乳素的昼夜节律，峰值催乳素和糖皮质激素峰值，为类似物种的瘦胰岛素敏感成分建立的血液水平，以每日定时序列治疗肥胖物种的身体脂肪沉积物的减少。 多巴胺激动剂在同一物种的瘦动物中发现的血浆催乳素浓度峰值之前或之后施用，并且在等离子体催乳素节律在瘦动物中达到峰值之前的时间施用催乳素刺激剂。 胰岛素抵抗和高胰岛素血症或高血糖或两者也可以通过与肥胖症治疗相对应的治疗长期控制。 短期每日注射在脑神经中枢复位激素时间产生长期效应。
-
9.发明授权Process for the long term reduction of body fat stores, insulin resistance, hyperinsulinemia in vertebrates 失效长期减少身体脂肪储存，胰岛素抵抗，脊椎动物高胰岛素血症的过程
公开(公告)号：US5496803A
公开(公告)日：1996-03-05
申请号：US287066
申请日：1994-08-08
IPC分类号： A61K31/00 , A61K31/13 , A61K31/15 , A61K31/166 , A61K31/195 , A61K31/221 , A61K31/35 , A61K31/352 , A61K31/40 , A61K31/405 , A61K31/435 , A61K31/439 , A61K31/445 , A61K31/4515 , A61K31/454 , A61K31/46 , A61K31/475 , A61K31/48 , A61K31/496 , A61K31/54 , A61K31/5415 , A61K31/55 , A61K31/551 , A61K31/5513 , A61K31/695 , A61K38/22 , A61K45/00 , A61K45/06 , A61P3/08 , A61P3/10 , C07D457/00 , C07D457/04 , G01N33/74 , C07K14/64 , A61K38/00 , C07K9/00
CPC分类号： A61K31/496 , A61K31/00 , A61K31/13 , A61K31/15 , A61K31/166 , A61K31/195 , A61K31/221 , A61K31/35 , A61K31/352 , A61K31/40 , A61K31/405 , A61K31/435 , A61K31/439 , A61K31/445 , A61K31/4515 , A61K31/454 , A61K31/46 , A61K31/475 , A61K31/48 , A61K31/4985 , A61K31/54 , A61K31/5415 , A61K31/55 , A61K31/551 , A61K31/5513 , A61K31/695 , A61K38/2257 , A61K45/06 , G01N33/74 , Y10S514/866
摘要： A process for the long-term modification and regulation of lipid metabolism--generally to reduce obesity, insulin resistance, and hyperinsulinemia (the three hallmarks of Type II diabetes)--by injections into the bloodstream of a vertebrate, animal or human, of prolactin, or both prolactin and a glucocorticosteroid. The injections are made over a limited period at a time of day dependent on the normal circadian rhythm of fat and lean members of a similar species. Decreases (or increases) in body fat deposits result by treatment of an obese species (lean species) on a daily timed sequence based on circadian rhythms of the peak prolactin, or peak prolactin and peak glucocorticosteroid, blood level established for lean members (or obese members) of a similar species. Insulin resistance, and hyperinsulinemia can also be controlled in humans on a long-term basis by treatment corresponding to that of the treatment for obesity. The short-term daily injections reset hormonal timing in the neural centers of the brain to produce long-term effects.
摘要翻译： 长期改变和调节脂质代谢的过程 - 通常通过注射到脊椎动物，动物或人类的催乳素的血液中来减少肥胖，胰岛素抵抗和高胰岛素血症（II型糖尿病的三个标志） 或催乳素和糖皮质激素两者。 注射是在一天的有限时间内进行的，取决于类似物种的脂肪和瘦成员的正常昼夜节律。 基于妊娠峰值催乳素的昼夜节律或峰值催乳素和高峰糖皮质激素，为精瘦成员（或肥胖）建立的血液水平，以每日定时序列治疗肥胖物种（瘦肉种）的减少（或增加） 成员）的类似物种。 胰岛素抵抗和高胰岛素血症也可以通过与肥胖症治疗相对应的治疗长期控制在人体内。 短期每日注射在脑神经中枢复位激素时间产生长期影响。
-
10.发明授权
公开(公告)号：US5468755A
公开(公告)日：1995-11-21
申请号：US158153
申请日：1993-11-24
IPC分类号： A61K31/00 , A61K31/13 , A61K31/15 , A61K31/166 , A61K31/195 , A61K31/221 , A61K31/35 , A61K31/352 , A61K31/40 , A61K31/405 , A61K31/435 , A61K31/439 , A61K31/445 , A61K31/4515 , A61K31/454 , A61K31/46 , A61K31/475 , A61K31/48 , A61K31/54 , A61K31/5415 , A61K31/55 , A61K31/551 , A61K31/5513 , A61K31/695 , A61K38/22 , A61K45/06 , G01N33/74 , A61K31/44
CPC分类号： G01N33/74 , A61K31/00 , A61K31/13 , A61K31/15 , A61K31/166 , A61K31/195 , A61K31/221 , A61K31/35 , A61K31/352 , A61K31/40 , A61K31/405 , A61K31/435 , A61K31/439 , A61K31/445 , A61K31/4515 , A61K31/454 , A61K31/46 , A61K31/475 , A61K31/48 , A61K31/4985 , A61K31/54 , A61K31/5415 , A61K31/55 , A61K31/551 , A61K31/5513 , A61K31/695 , A61K38/2257 , A61K45/06 , Y10S514/866
摘要： A process for the long term modification and regulation of lipid and carbohydrate metabolism--generally to reduce obesity, insulin resistance, and hyperinsulinemia or hyperglycemia, or both (these are the hallmarks of noninsulin dependent, or Type II diabetes)--by administration (i.e., by oral, sublingual or parenternal administration) to a vertebrate, animal or human, of a dopamine agonist, e.g., bromocriptine. Administration of the bromocriptine is made over a limited period at a time of day dependent on the normal circadian rhythm of insulin resistant and insulin sensitive members of a similar species. Insulin resistance, and hyperinsulinemia and hyperglycemia, or both, can be controlled in humans on a long term basis by such treatment inasmuch as the short term daily administration resets hormonal timing in the neural centers of the brain to produce long term effects.
摘要翻译： 长期改变和调节脂质和碳水化合物代谢的过程 - 通常通过给药（即，通过给药（例如，通过给药）而减少肥胖，胰岛素抵抗和高胰岛素血症或高血糖或两者（这些是非胰岛素依赖型或II型糖尿病的特征） 通过口服，舌下或本体给药）到脊髓动物或动物或人类的多巴胺激动剂，例如溴隐亭。 溴隐亭的施用在一天的有限时间内取决于相似物种的胰岛素抵抗和胰岛素敏感成员的正常昼夜节律。 胰岛素抵抗和高胰岛素血症和高血糖或两者都可以通过这种治疗长期控制在人类中，因为短期每日给药复位脑神经中枢的激素时间以产生长期效应。
-
-
-
-
-
-
-
-
-
搜索结果
67 条记录 (耗时 0.03 秒)
